ImmunoGen Announced Findings From Two Subset Analyses Of The Phase 3 MIRASOL Trial Of Elahere Compared To Chemotherapy For Ovarian Cancer, Showing Overall And Progression-free Survival Benefit Regardless Of Prior Therapies
Portfolio Pulse from Benzinga Newsdesk
ImmunoGen has announced findings from two subset analyses of the Phase 3 MIRASOL trial of Elahere compared to chemotherapy for ovarian cancer. The results show overall and progression-free survival benefit regardless of prior therapies.
September 28, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunoGen's positive trial results for Elahere could potentially boost its stock as it indicates a successful development in their product pipeline.
The positive results from the Phase 3 MIRASOL trial of Elahere indicate a successful development in ImmunoGen's product pipeline. This could potentially attract more investors, leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100